The B7-H4 Targeting Therapies Market signals an exciting new chapter in our ongoing battle against cancer. After years of groundbreaking progress with PD-1/PD-L1 and CTLA-4 inhibitors that have transformed outcomes for countless patients, researchers have identified B7-H4 as the next frontier—a fresh target offering renewed hope for patients who need new options. B7-H4 isn't...